TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03574155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pre-operative Counseling and Education
Description: Group control Pre-operative Orientation Routine Application of the questionnaire (ESAS) and (HADS) Post-operative Immediate (1 OP) Application of the Questionnaire to assess HADS and ESAS Anxiety (Patient)~Experimental Group Pre-operative Counseling and Education Application of the questionnaire (ESAS) and (HADS)~Late postoperative (2 - 4 weeks) Questioning the patient and companion evaluating the degree of satisfaction regarding the preoperative guidelines.
Study: NCT00752323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aminolevulinic acid
Description: Given orally

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical resection - 6 biopsies from 3 fluorescent regions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical resection - 6 biopsies from 3 fluorescent regions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical resection - 6 biopsies from 3 fluorescent regions

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical resection - 6 biopsies from 3 fluorescent regions
Study: NCT03330756

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic Roux-en-Y gastric bypass
Description: laparoscopic Roux-en-Y gastric bypass with a 50 cm biliary limb and a 150 cm alimentary limb

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic Mini gastric bypass
Description: laparoscopic Mini gastric bypass with a gastrojejunostomy at 200 centimeters measured from the ligament of Treitz
Study: NCT04230109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan
Description: Sacituzumab Govitecan via iv, predetermined dosage per protocol, two days per 21-day cycle, for 4 cycles (monotherapy cohort)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab via iv, predetermined dosage per protocol, per 21-day cycle, for 4 cycles (combination cohort)
Study: NCT04002245

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antiseptic application
Description: The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: antiseptic application
Description: The application of the antiseptic on the healthy and visibly clean skin of the bend of the elbow will be carried out for all participant
Study: NCT00400660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK615915A
Description: GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK615915A
Description: GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK615915A
Description: GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK615915A
Description: GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK615915A
Description: GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
Study: NCT01760421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
Study: NCT00400660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo inhaler.
Study: NCT01670981

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ixmyelocel-T
Description: 12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
Study: NCT02334566

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NET TX
Description: Intervention procedures are a behavioral intervention (NET \& KIDNET) with 8-12 sessions administered on a weekly basis.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NET TX
Description: Intervention procedures are a behavioral intervention (NET \& KIDNET) with 8-12 sessions administered on a weekly basis.
Study: NCT04670692

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 5G-MCE examination
Description: The endoscopist (W.Z.) manipulated the two joysticks on the remote console (based in Shanghai). Then the remote control software and remote connection software takes the endoscopist's input and translates it into a control signal. After network transmission, the patient side cart (based in Yinchuan) translates the control signal into actual instrument manipulation and mobilize the robotic magnetic arm, and simultaneously driving the precise movement and rotation of the capsule to perform the gastric and duodenum examination. Meanwhile, the images captured by the capsule are simultaneously sent back to the screen of the remote console, and thus provide guidance for better control of the capsule.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MCE examination
Description: The endoscopist (W.Z.) performs the MCE examination procedure conventionally. And communicate with the volunteer face to face in the same examination room.
Study: NCT01387555

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JX-594 recombinant vaccina GM-CSF
Description: Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
Study: NCT04194567

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Black Ragi
Description: Pancakes made out of the dark ragi

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: White Ragi
Description: Pancakes made out of the white ragi
Study: NCT02826200

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acenocoumarol
Description: Standard of care plus oral anticoagulant therapy (acenocoumarol)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT02958592

Intervention type: OTHER
Intervention: two-dimensional shear-wave elastography (SWE)
Description: performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
Study: NCT00779389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150mg will be taken once a day for 14-21days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib + Placebo
Description: Dasatinib (100 mg) once a day for 14-21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib plus Dasatinib
Description: Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 14-21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg for 14-21 days.
Study: NCT04065100

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sebum test
Description: Measuring sebum in newborn

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sebum test
Description: Measuring sebum in newborn
Study: NCT03649620

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: unripe Bokbunja Extract
Description: tablet(1 tablet/d, 600 mg/d) for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: unripe Bokbunja Extract
Description: tablet(1 tablet/d, 600 mg/d) for 12 weeks
Study: NCT00400660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo inhaler.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects will also receive placebo inhaler.
Study: NCT00187681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 2 doses of Metformin Day 1 1000mg, Day 2 850 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 2 doses of Metformin Day 1 1000mg, Day 2 850 mg
Study: NCT01167673

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: coltect
Description: green tea 250 mg, selenium 100 micro gram, curcumin 500 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT03604393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Description: For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Description: For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Description: For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Description: For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
Study: NCT03649620

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for 12 weeks
Study: NCT03604393

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Description: For this intervention, ORPRN Practice Facilitators will: 1) Build practice QI capacity by addressing the five Change Concepts; 2) Train practice clinicians and staff to generate reminder lists and notices in ALERT Immunization Information System (state immunization registry); 3) Develop an HPV immunization improvement plan for each practice using PDSA cycles and workflow mapping; and 4) Facilitate community engagement surrounding HPV vaccination messaging.
Study: NCT02609620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Peristaltic Feeding Tube

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ConvaTec Levin Duodenal Tube
Study: NCT00995501

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin - Placebo
Description: Insulin to maintain blood glucose 180-200 mg/dl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Insulin - Placebo
Description: Insulin to maintain blood glucose 180-200 mg/dl.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia management -Placebo
Description: Deep anesthesia to maintain BIS about 35

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anesthesia management -Placebo
Description: Deep anesthesia to maintain BIS about 35

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia management -Placebo
Description: Deep anesthesia to maintain BIS about 35

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Anesthesia management -Placebo
Description: Deep anesthesia to maintain BIS about 35
Study: NCT03076476

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bioresorbable Vascular Scaffolds (BVS)
Description: Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug-Eluting Stent (DES) - slow
Description: Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.~After the interim analysis DES-slow to be compared with BVS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Drug-Eluting Stent (DES) - standard(std)
Description: Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
Study: NCT03357614

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem
Description: Antibiotic therapy for complicated UTI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulopenem-Etzadroxil/Probenecid
Description: Antibiotic therapy for complicated UTI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Antibiotic therapy for complicated UTI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Antibiotic therapy for complicated UTI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin-clavulanate
Description: Antibiotic therapy for complicated UTI
Study: NCT03381261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Injection of Botulinum toxin type A in back of head
Study: NCT01376323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 1mg
Description: GSK256073 1mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 1mg
Description: GSK256073 1mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 5mg
Description: GSK256073 5mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 5mg
Description: GSK256073 5mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 10mg
Description: GSK256073 10mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 10mg
Description: GSK256073 10mg capsule
Study: NCT01053663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamiflu
Description: 10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
Study: NCT02857244

Intervention type: DRUG
Group type: OTHER
Intervention: Duloxetine
Description: Patients will first receive Duloxetine for 4 weeks starting at 30mg, 60mg, 90mg then 120mg (if tolerated). Increases in dosage amounts will occur every week.

Intervention type: DRUG
Group type: OTHER
Intervention: Donepezil
Description: Patients will receive Donepezil after 4 weeks of dosing with Duloxetine. Patients will receive Donepezil in combination with the highest dose of Duloxetine that was tolerated. Patients will remain on this for 2 weeks with increasing doses at each week. One week of 5mg, one week of 10mg.

Intervention type: DRUG
Group type: OTHER
Intervention: Modafinil
Description: Patients will receive Modafinil after a 4 week washout period (after dosing with donepezil \& duloxetine in combination). Patients will receive Modafinil for two weeks with increasing doses at each week. One week at 100mg, one week at 200mg.
Study: NCT02211482

Intervention type: DRUG
Group type: OTHER
Intervention: dolutegravir, lamivudine
Description: single arm
Study: NCT00971607

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen + Sevoflurane
Description: Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxygen (placebo)
Description: Control will receive oxygen only.
Study: NCT00003416

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Study: NCT02683395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX51107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX51107
Study: NCT01844648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NH004 tropicamide
Description: Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NH004 Placebo
Description: Intra-oral slow dissolving muco-adhesive thin film
Study: NCT04296825

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Camel milk containing Bifidobacterium animalis A6
Description: Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Study: NCT01376323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 25mg
Description: GSK256073 25mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK256073 25mg
Description: GSK256073 25mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study: NCT04296825

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Camel milk
Description: Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bifidobacterium animalis A6
Description: Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow milk
Description: Take the interventions about 30 minutes after meals in the morning and evening for 4 consecutive weeks.
Study: NCT06046664

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ONCOTYPE DX DCIS test
Description: The Oncotype DX DCIS score, comprised of 12 of the 21 genes of the Oncotype DX Recurrence score, has been developed by Genomic Health Inc.~Two clinical utility studies have now been performed in USA, assessing the value of the Oncotype DX DCIS to clinical decision making (18,19) The first study by Alvarado et al. evaluated the influence of the test in 10 centres and in 115 patients (18). The DCIS score led to a change in the treatment recommendation in 36 patients (31.3%; 26 patients had a change to no radiation and 10 patients had a change to recommend radiation). The second study similarly showed change in recommendations following the Oncotype DX DCIS test in 26.4% of cases. It is unclear what the impact of the DCIS score test would be in the UK.
Study: NCT01595009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus (RAD001)
Description: Everolimus was supplied as tablets of 5mg strength.
Study: NCT00684333

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: painless subcutaneous injection by EZ-Ject Injector
Description: EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
Study: NCT03882164

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood-Bile Ratio of Tacrolimus
Description: Diagnosis of early transplanted liver dysfunction to adjust Tacrolimus dose adminstered
Study: NCT01919632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: health-behavior seminar and endurance exercise
Description: The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
Study: NCT03496870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opicapone
Description: catechol-O-methyltransferase (COMT) inhibitor
Study: NCT01376323

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100mg
Description: Sitagliptin 100mg capsule
Study: NCT00454571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leuprolide acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leuprolide acetate
Study: NCT03088124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Patients will take orally everyday 240 mg of Apalutamide.
Study: NCT00454571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: goserelin acetate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: goserelin acetate
Study: NCT03496870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carbidopa Levodopa
Description: Levodopa: dopamine precursor Carbidopa: DOPA decarboxylase inhibitor